Christopherw Ryan News Today

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.

Adjuvant everolimus improves recurrence-free survival in patients with fully resected renal cell carcinoma who have a very high risk of disease recurrence.

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

Adjuvant everolimus improves recurrence-free survival in patients with fully resected renal cell carcinoma who have a very high risk of disease recurrence.